What happened with TYRA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tyra Biosciences is a clinical-stage biotechnology company developing oral drugs for cancers and genetically defined conditions, with a focus on FGFR proteins. Its candidates include dabogratinib for urothelial cancers and skeletal dysplasia. Its SNÅP platform uses protein structures and laboratory and animal testing to refine drug designs. Tyra wholly owns its pipeline and retains development and commercialization rights.
The company has no revenue and has funded its work mainly by raising equity capital rather than selling medicines. If its drugs receive approval, it plans to sell them itself or with partners. Future sales would depend on government programs, private insurers and other payors providing coverage and adequate reimbursement. Tyra has not yet built sales, marketing or distribution capabilities.
The business depends on continued funding and on its candidates completing clinical development and obtaining regulatory approval; Tyra cannot market them in the United States without FDA approval. It also relies on outside manufacturers for trial supplies and would continue using them for commercial production if a drug is approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tyra's value hinges on clinical success and differentiation of its FGFR medicines, with Taiho's Lytgobi and Elevar's lirafugratinib also worth watching as competitors in FGFR2-driven cholangiocarcinoma.
BridgeBio's oral infigratinib competes with Tyra's dabogratinib in development for achondroplasia, making its late-stage clinical results more relevant to Tyra than sales of its heart-disease drug Attruby. Watch infigratinib's results in patients with achondroplasia as a benchmark for Tyra's program.
BioMarin's marketed Voxzogo and developing BMN-333 compete with Tyra's dabogratinib for achondroplasia and related skeletal conditions. Voxzogo generated $926.9 million in net product revenue in 2025; its sales expansion is the concrete commercial benchmark to watch for Tyra's skeletal-disease program.
UroGen already sells Jelmyto for low-grade upper-tract urothelial cancer and Zusduri for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, competing in patient groups targeted by Tyra's oral dabogratinib. Its products release mitomycin locally over several hours, making their treatment results a useful comparison for Tyra's oral approach.
Ascendis Pharma's TransCon CNP competes for children with achondroplasia, overlapping with Tyra's dabogratinib skeletal-dysplasia program. Follow TransCon CNP's clinical and regulatory news in those children rather than sales of Ascendis' adult hypoparathyroidism treatment YORVIPATH.
Cogent Biosciences' clinical FGFR2/3 inhibitor program competes with Tyra's FGFR-focused cancer pipeline, including TYRA-200 for FGFR2-driven intrahepatic cholangiocarcinoma. Results from that program—not Cogent's more advanced bezuclastinib program—are the direct comparison to watch for Tyra.
CG Oncology's investigational cretostimogene overlaps with Tyra's dabogratinib in intermediate-risk non-muscle-invasive bladder cancer. Watch results in that patient group: CG Oncology is developing a treatment designed to destroy tumor cells and trigger an immune response, while Tyra is developing an oral small-molecule medicine.
Incyte already sells Pemazyre for cholangiocarcinoma with FGFR2 alterations, giving Tyra's TYRA-200 an approved competitor in its target disease. Pemazyre's treatment results are the relevant benchmark for Tyra, rather than Incyte's broader blood-disease and inflammation businesses.
Relay Therapeutics receives milestone payments from Elevar, which holds global rights to develop and sell lirafugratinib, an FGFR2 inhibitor competing with Tyra's TYRA-200 in cholangiocarcinoma. Watch Elevar's development progress and the resulting milestone payments to Relay, rather than treating Relay's license revenue as drug sales.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin's report will show how Voxzogo sales are developing, giving Tyra Biosciences a commercial-market reference for its achondroplasia program.
Look at Voxzogo product sales and whether they are growing. Continued growth would show an expanding market for an existing achondroplasia treatment, giving Tyra's program a clearer commercial reference; flat or falling sales would leave demand for a treatment market less certain. This speaks to the market, not to Tyra's candidate's efficacy.
BridgeBio Pharma, Inc. earningsBBIO
BridgeBio Pharma's report will show infigratinib's clinical progress in achondroplasia, a direct development comparison for Tyra Biosciences' dabogratinib.
Look for infigratinib trial progress, especially results in people with achondroplasia and whether the study advances. Meaningful progress would show a competing program moving forward in the same patient group, putting more focus on Tyra's clinical and development challenge; limited results or delays would leave a less advanced competitor to compare against, but would not prove dabogratinib works.
Fed Interest Rate Decision
Tyra earns interest on its cash, cash equivalents and marketable securities, so Fed rate decisions can change the interest income that offsets its research and development and other operating costs.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift the interest Tyra earns on its cash and securities, partly offsetting operating costs; the benefit depends on the balances held and how quickly their yields adjust.
If it comes in below expectations
Lower rates can reduce the interest Tyra earns on its cash and securities, leaving less other income to offset operating costs; the effect depends on its balances and how quickly their yields adjust.
Incyte Genomics Inc earningsINCY
Incyte's report will show how Pemazyre, an approved FGFR2-targeted drug, is being used for cholangiocarcinoma, a market Tyra Biosciences' TYRA-200 targets.
Focus on Pemazyre's use or sales for FGFR2-altered cholangiocarcinoma, not Incyte's other businesses. Broader use would show an approved treatment serving the disease group TYRA-200 targets and strengthen the commercial competition benchmark; limited or weakening use would make that benchmark less compelling, but would not establish TYRA-200's efficacy.
Tyra Biosciences, Inc. earningsThis company
Tyra Biosciences has no product sales, so its report will show whether clinical-trial spending is still supported by its cash resources.
Read research and development spending alongside cash used in operations. Rising trial spending with faster cash use would mean Tyra is spending its funds more quickly to advance its programs, putting its plan to fund operations through at least 2027 under greater pressure. Slower spending and cash use would leave more room to run the trials. The test is whether Tyra can advance its programs without materially shortening its funding runway.
